Pharmacokinetic Profile of a Low-Molecular Weight Heparin (Reviparin) in Pregnant Patients A Prospective Cohort Study**The results of this paper were presented at the International Society of Thrombosis and Hemostasis Meeting in Washington D.C. in August of 1999.

Anticoagulant therapy during pregnancy is problematic. Patients are frequently treated with long-term low-molecular weight heparin despite a lack of evidence for its effectiveness, and in the absence of validated dosing recommendations. The objectives of this investigation were to characterize the safety and pharmacokinetic behavior of a low-molecular weight heparin (reviparin) administered throughout pregnancy. Forty-two patients followed in a …